WEDNESDAY – FEBRUARY 7

6:30 pm - 8:30 pm 
Welcome Reception

12:15 pm  – Luncheon Symposium
The Hematology Circle:  Stem Cell Transplant in the Era of Immunomodulatory Drugs and Other Novel Therapies
(Supported by Celgene Corporation)

8:30 am
Advances in Chronic GVHD:  Confronting Our Greatest Challenge
   ■ Chronic GVHD:  What Do We Really Know and How Can We Learn More?
          Warren D. Shlomchik, MD
   ■ Measuring Response in Chronic GVHD
          Steven Z. Pavletic, MD, and Stephanie J. Lee, MD, MPH
   ■ What's New in the Treatment of Chronic GVHD:  Anything Better than Steroids?
          Daniel R. Couriel, MD

8:30 am
Mesenchymal Stem Cells
   ■ MSCs:  The Makings of a Cell for Cellular Therapy
          Edwin M. Horwitz, MD, PhD
   ■ Mesenchymal Stem Cells for the Treatment of GVHD
          Francesco Frassoni, MD
   ■ MSCs as Tumor-Targeting Drug Delivery Systems
          Michael Andreeff, MD, PhD

10:30 am
Dendritic Cells in Transplantation and Immune-Based Therapies
   ■ Dendritic Cells at the Crossroads of Innate and Adaptive Immunity
          James W. Young, MD
   ■ The Role of Dendritic Cells in GVHD
          Miriam Merad, MD, PhD
   ■ Dendritic Cell Biology in Clinical Hematopoietic Stem Cell Transplantation
          Derek N. J. Hart, MD, PhD

10:30 am
Measures of Morbidity:  Functional Assessment and Cytokines
   ■ Functional Assessment, Symptoms and Cytokines – Initial Studies at MDACC
          Sergio A. Giralt, MD
   ■ Functional Assessment Tests:  What Are They, What Do They Measure, What Have
      We Learned from Them?
          Maureen J. Simmonds, PhD, PT
   ■ Improving Fraility – Functional Assessment Tools and Other Biologic Markers – Relevance
      to Intensive Therapies
           Roy G. Smith, PhD

10:30 am
Multiple Myeloma:  Controversies in Treatment
   Bart Barlogie, MD, PhD, and A. Keith Stewart, MB, ChB

7:15 am  – Breakfast Symposium
Extracorporeal Photopheresis:  Defining a Role in the Treatment of Chronic GVHD
(Supported by THERAKOS, Inc.)

8:30 am
Regulatory T-Cells:  History, Laborary and Clinical Uses
   ■ Regulatory T-Cells:  Historical Overview
          Nelson J. Chao, MD
   ■ Regulatory T-Cells in Immunologic Tolerance to Self and Organ Transplants
          Shimon Sakaguchi, MD
   ■ The Promise and Challenges of Human Regulatory T-Cells in the Clinic
          Robert Negrin, MD

11:00 am
Mortimer M. Bortin Lecture
   Evolution of Clinical Research in HCT
   Mary M. Horowitz, MD, MS

12:15 pm  – Luncheon Symposium
Challenging Issues in the Prevention and Management of Patients with Invasive Fungal Infections
(Supported by Astellas Pharma US, Inc.)

1:30 pm

BMT Medical Directors Conference

Quality Outcomes Reporting:  Getting Ready for HRSA's New Requirements

(Supported by Baxter International, Inc., Cellular Therapies)

   ■ ASBMT, the C.W. Bill Young Transplantation ACT, and Quality Outcomes Reporting: 
      An Update
          Roy B. Jones, MD
   ■  Solid Organ Transplantation and Outcomes Reporting:  An Analysis
          Ian Jamieson, MBA, MHA
   ■  AGNIS:  A Growable Network for Information Sharing
          Dennis L. Confer, MD
   ■ CIBMTR and the Stem Cell Transplantation Outcomes Database (SCTOD)
          J. Douglas Rizzo, MD, MS
   ■ How Can Centers Respond? – General
          Patrick Stiff, MD
   ■ How Can Centers Respond? – Informatics
          Roy B. Jones, MD
 

3:00 pm
Regulatory Affairs Session
   ■ FDA Regulatory Approach to Hematopoietic Stem/Progenitor Cells:  What's New
      Since Honolulu (February 2006)
          Ellen F. Lazarus, MD
          FDA Center for Biologics Evaluation and Research
   ■ FDA Inspections:  The Transplant Center Perspective
          Patrick Stiff, MD
   ■ Adverse Event Reporting Scenarios
          John D. McMannis, MD

4:30 pm
Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation:  Current Perspectives
 ■ Non-myeloablative Hematopoietic Cell Transplantation Using Low-Dose TBI-Based
    Conditioning Regimens
           Brenda M. Sandmaier, MD
   ■ Alemtuzumab Prevents GVHD Following Reduced-Intensity Transplant for Lymphoma
      and Allows Adoptive Immunotherapy to Promote GVL Responses
          Stephen Mackinnon, MD
   ■ Graft-versus-Solid Tumor:  From Bedside to Bench
          Richard Childs, MD

4:30 pm
Myeloproliferative Disorders
   ■ Molecular Origins of Myeloproliferative Disorders
          Josef Prchal, MD
   ■ Clinical Outcomes and Treatment of Myeloproliferative Disorders
          Ronald Hoffman, MD
   ■ Allogeneic Stem Cell Transplantation for Patients with Myeloproliferative Disorders
          Damiano Rondelli, MD

4:30 pm
Key Studies from the CIBMTR and the EBMT
   Sergio A. Giralt and Dietger Niederwieser
   ■ The Likelihood of HCT in the United States 
          Marcelo Pasquini, MD, MS
   ■ Single or Multiple HLA-A, B, C or DRB1 Mismatches Limit Success of Unrelated Donor
      Bone Marrow Transplantation
          Stephanie J. Lee, MD, MPH
   ■ Data from the Prevenar Study of Pneumococcus Vaccination
          Per Ljungman, MD

   ■ Autologous Stem Cell Transplantation in HIV Associated Lymphoma Patients:  The EBMT
      Lymphoma Working Party Experience 
           Pascual Balsalobre